Our innovative human‐based neural model of cellular mosaicism has clear utility for MECP2 and other X‐linked genetic disorders, and the concept can likewise be expanded to include other aspects of pharmacogenomic precision medicine, such as characterizing pharmacological response or variation in cytotoxicity for patients with novel mutations. The gene discussed is MECP2; the disease is hereditary disease.